Sake, Svenja M.
Zhang, Xiaoyu
Rajak, Manoj Kumar
Urbanek-Quaing, Melanie http://orcid.org/0000-0002-3629-9011
Carpentier, Arnaud http://orcid.org/0000-0002-6994-4689
Gunesch, Antonia P.
Grethe, Christina
Matthaei, Alina
Rückert, Jessica
Galloux, Marie
Larcher, Thibaut http://orcid.org/0000-0002-0396-3190
Le Goffic, Ronan http://orcid.org/0000-0002-2012-0064
Hontonnou, Fortune
Chatterjee, Arnab K.
Johnson, Kristen http://orcid.org/0000-0003-0788-7217
Morwood, Kaycie
Rox, Katharina http://orcid.org/0000-0002-8020-1384
Elgaher, Walid A. M. http://orcid.org/0000-0002-8766-4568
Huang, Jiabin http://orcid.org/0000-0002-3480-7115
Wetzke, Martin
Hansen, Gesine
Fischer, Nicole
Eléouët, Jean-Francois
Rameix-Welti, Marie-Anne http://orcid.org/0000-0002-5901-3856
Hirsch, Anna K. H. http://orcid.org/0000-0001-8734-4663
Herold, Elisabeth
Empting, Martin http://orcid.org/0000-0002-0503-5830
Lauber, Chris http://orcid.org/0000-0002-2265-2953
Schulz, Thomas F. http://orcid.org/0000-0001-8792-5345
Krey, Thomas http://orcid.org/0000-0002-4548-7241
Haid, Sibylle http://orcid.org/0000-0001-5699-3097
Pietschmann, Thomas http://orcid.org/0000-0001-6789-4422
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EXC 2155 RESIST, Project 390874280, EXC 2155 “RESIST” – Project ID 390874280, EXC 2155 “RESIST” – Project ID 390874280, EXC 2155 “RESIST” – Project ID 390874280, EXC 2155 “RESIST” – Project ID 390874280, EXC2155 RESIST_390874280)
Niedersächsisches Ministerium für Wissenschaft und Kultur (INDIRA 11-76251-99-6/19 (ZN3437))
Volkswagen Foundation (OPTIS, Project ID 9B811, OPTIS, Project ID 9B811, OPTIS, Project ID 9B811, OPTIS, ID9B811)
Helmholtz International Lab for anti-infectives
Deutsches Zentrum für Infektionsforschung (DZIF, TTU 09.719)
Niedersächsische Ministerium für Wissenschaft und Kultur (INDIRA 11-76251-99-6/19 (ZN3437))
Article History
Received: 19 December 2022
Accepted: 16 January 2024
First Online: 8 February 2024
Competing interests
: SMS, SH, JR, TFS and TP disclose that they are authoring a patent application “LONAFARNIB FOR USE IN THE TREATMENT OF VIRAL INFECTIONS” describing lonafarnib as antiviral compound that inhibits RSV infection (21152993.8-1132). The authors declare no competing interests and no restrictions on the publication of data.